Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
Home Innovation Flow Neuroscience receives Series A funding to make self-managed medical device available globally
Innovation

Flow Neuroscience receives Series A funding to make self-managed medical device available globally

by jcp August 10, 2021
August 10, 2021
gawdo

Five global investors back revolutionary depression treatment 

10.08.2021 – Flow Neuroscience, creator of Europe’s only medically approved transcranial direct current stimulation (tDCS) device and behavioural therapy app for depression, has closed its Series A investment round led by Khosla Ventures, CSS group through Swiss Health Ventures and Zühlke Ventures. The funding will advance its existing depression treatment to be more patient-specific and will accelerate the development of non-pharmaceutical self-managed solutions for other mental health disorders, such as anxiety and drive US expansion through clinical trials and FDA approval.

The planned expansion follows Flow’s success in treating patients across the UK and EU for the past two years, with its unique headset that delivers gentle stimulation using the tDCS technique to combat depression. The investment round will enable the company to strengthen its offering to the European market, servicing patients in their native language, as well as preparing for US market entry.

From Sweden to the world

The Swedish born med-tech company founded by clinical psychologist Daniel Månsson, and neuroscientist Erik Rehn has grown from humble beginnings to fill the treatment gap between medication and therapy, with its first solution – the Flow headset – being the only drug-free, at-home tDCS depression treatment of its kind to be medically approved.

Global investors have come together to support Flow’s endeavour to branch out internationally – a strong endorsement for the cutting edge treatment method. Led by Khosla Ventures, CSS Group through Swiss Health Ventures and Zühlke Ventures, the round was also joined by Kirin Holdings through Kirin Health Innovation fund led by Global Brain, a top venture capital based in Japan, SOSV’s HAX, as well as the leading San Francisco based patent firm Schox. The cross-continental participants will fuel Flow Neuroscience’s core mission to create innovative treatments for mental health disorders that have no side effects, are easily accessible and empower patients and clinicians.

Backing tech for mental health

Michael Rieger, Head Innovation Operations & Portfolio at CSS Group comments: “Flow offers completely new ways of treating clinical depression by applying a technology that has not been available to the general public until now. CSS is investing in Flow so as to grant patients access to this therapy approach and thus to close a gap in the healthcare system.”

Dr. Patrick Griss, Executive Partner at Zühlke, adds: “We look for truly disruptive technologies that drive positive change in the world and with Flow we’ve found that. A treatment that addresses the negative side effects seen with antidepressants and that allows autonomy in how patients can treat their health conditions, is something we are passionate to develop further.”

Further to this, the investment from Khosla Ventures, leading US venture capital firm, and Global Brain Corporation together with Kirin holdings, will enable Flow to expand its treatment to the US and APAC, funding clinical trials that will pave the way for market access to patients and clinicians.

Alexander Morgan, MD PhD, Principal at Khosla Ventures adds from Khosla says: “We are happy to see continued progress with Flow’s medication-free treatment for depression and to reaffirm our commitment to the next stages of global expansion together. Bringing this portable, self-managed treatment to US patients will create a scalable, accessible solution to support the millions of people living with depression.”

Supporting Healthcare Systems and Enabling accessible treatments

Looking to the future, Flow aims to increase its reach and accessibility to ultimately cure and manage mental health disorders. By providing a digital and remote device, Flow is revolutionising scientific research into the effects of tDCS on depression as researchers can recruit more participants and run trials at a much greater pace, without reliance on in-clinic participation. This allows for scalable expansion globally through clinical trial validation and through the development of a similar solution for anxiety.

Daniel Månsson, clinical psychologist and co-founder of Flow Neuroscience, explains: “With accessibility at the forefront, we have a three-fold mission at Flow over the coming years; to advance our current treatment to be more patient-specific and to treat more people suffering from depression; To accelerate our collaboration with healthcare systems to provide alternative options for clinicians to prescribe and a complementary solution to reduce waiting times; And, to work in collaboration with researchers in the field of tDCS to validate further self-managed treatment solutions for a wider range of mental health disorders, such as anxiety.”

www.gawdo.com
Share on FacebookShare on TwitterShare on Linkedin
0 FacebookTwitterPinterestEmail
previous post
Why you should invest in sustainability marketing
next post
Deliveroo reports doubling in gross order value in first half

You may also like

Boots Launches INNOVATE Agile Incubator, Powered by TCS...

July 27, 2022

Valkyrie ushers in age of THE highest-fidelity motion...

July 21, 2022

Sales innovation success at IRIS Software Group using...

July 19, 2022
Editorial & Advertiser disclosureEditorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gawdo.com
https://www.gawdo.com
  • About us
  • Advertising & Terms of Use
  • Contact Us
  • Privacy Policy

@2021 - All Right Reserved.


Back To Top
Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT